araag2/HINT huggingface dataset:
Clinical trial NCT00086320 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone er
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  DSM-IV diagnosis of schizophrenia at least 1 year before screening

          -  experiencing an acute schizophrenic episode with a total PANSS score between 70 and
             120

          -  agree to be hospitalized for a minimum of 14 days at the start of the study

          -  capable of administering study medication themselves or have assistance with study
             medication administration consistently available throughout the study

          -  resided at the same address continuously for at least 30 days prior to screening

          -  able and willing to fill out self administered questionnaires

          -  washout of antiparkinsonian medications, beta-blockers

          -  antiepileptics, lithium 3 days prior to the start of the run-in phase

        Exclusion Criteria:

          -  DSM-IV Axis I diagnosis other than schizophrenia

          -  DSM-IV diagnosis of substance dependence within 6 months prior to screening (nicotine
             and caffeine dependence are not exclusionary)

          -  preexisting severe gastrointestinal narrowing (pathologic or iatrogenic)

          -  injection of a depot antipsychotic within 120 days before screening, or use of
             paliperidone palmitate within 10 months before screening

          -  previous history of lack of response to risperidone when acutely psychotic

          -  history of neuroleptic malignant syndrome

          -  significant risk of suicidal or violent behavior
Clinical trial NCT00168324 (phase 3, status: completed)
Conditions: macular edema, retinal vein occlusion
ICD codes: H59.033, H34.8130, H59.031, H59.032, H59.039, H34.8110, H34.8120, H34.8131, H34.8132, H34.8111, H34.8121, H34.8191, H34.8331, H34.8112
Drugs: 700 µg dexamethasone, 350 µg dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older with macular edema resulting from retinal vein occlusion

          -  Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or
             worse)

          -  Visual acuity in other eye no worse than 20/200

        Exclusion Criteria:

          -  Known anticipated need for ocular surgery within next 12 months

          -  History of glaucoma or current high eye pressure requiring more than 1 medication

          -  Diabetic retinopathy

          -  Uncontrolled systemic disease

          -  Known steroid-responder

          -  Use of systemic steroids

          -  Use of warfarin/heparin
Clinical trial NCT01316094 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: asp1941, placebo
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  type 2 diabetes mellitus patient

          -  subject has been on an exercise program and stable diet, or one oral hypoglycemic
             agent (alpha-glucosidase inhibitor, sulfonylurea agent and pioglitazone)

          -  estimated GFR value based on the Japanese GFR estimation equation of ≥ 30 mL/min/1.73
             m2 and < 90 mL/min/1.73 m2

          -  HbA1C value between 6.5 and 8.5%

          -  body mass index (BMI) 29.0 - 45.0 kg/m2

        Exclusion Criteria:

          -  type 1 diabetes mellitus patients

          -  proliferative diabetic retinopathy

          -  subject has received insulin within 12 weeks before the study

          -  subject has a chronic disease which requires the continuous use of adrenocortical
             steroids, immunosuppressant, and loop diuretic

          -  serum creatinine > upper limit of normal

          -  proteinuria (albumin/creatinine ratio > 300mg/g)

          -  dysuria and/or urinary tract infection, genital infection

          -  significant renal, hepatic or cardiovascular diseases

          -  severe gastrointestinal diseases
Clinical trial NCT01044459 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: aclidinium bromide 200 µg, aclidinium bromide 400 µg
SMILES: OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for
             Chronic Obstructive Lung Disease (GOLD) guidelines, 2010; postbronchodilator FEV1/FVC
             < 70%, and postbronchodilator FEV1 ≥ 30% and < 80% predicted

          -  Current or former cigarette smokers

        Exclusion Criteria:

          -  Patients who have been hospitalized for an acute COPD exacerbation within 3 months
             before the first visit

          -  Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1

          -  Patient with any clinically significant respiratory conditions other than COPD,
             cardiovascular conditions or mental illness

          -  History or presence of asthma verified from medical records

          -  Chronic use of oxygen therapy greater than or equal to 15 hours per day

          -  Patient with uncontrolled infection due to HIV and/or active hepatitis

          -  Patients with a history of hypersensitivity reaction to inhaled anticholinergics

          -  Patients with clinically significant cardiovascular conditions, including myocardial
             infarction during the previous 6 months, newly diagnosed arrhythmia within the
             previous 3 months, unstable angina, unstable arrhythmia that had required changes in
             pharmacological therapy or other intervention.
Clinical trial NCT00235911 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol turbuhaler
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosis of mild to moderate asthma, FEV1 ³ 60% of predicted normal values
             pre-bronchodilator, daily use of inhaled GCS during the last 3 months

        Exclusion Criteria:

          -  Regular need of >4 inhalations of a short-acting b2-agonist/day, known or suspected
             hypersensitivity to any of the investigational drugs or inhaled lactose, use of any
             b-blocking agent, having smoked ³10 pack-years
Clinical trial NCT00401193 (phase 3, status: completed)
Conditions: menorrhagia, heavy menstrual bleeding
ICD codes: G43.831, G43.839, G43.821, G43.829, N94.9, N94.89
Drugs: tranexamic acid tablets, tranexamic acid tablets, placebo tablets
SMILES: NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women with menorrhagia

          -  18-49 years of age

          -  Regularly occurring menstrual periods

        Exclusion Criteria:

          -  History or presence of clinically significant disease or abnormalities that may
             confound the study

          -  History of bilateral oophorectomy or hysterectomy

          -  Hormone therapy for birth control
Clinical trial NCT00363948 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, sitagliptin phosphate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus on diet/exercise therapy and metformin as
             monotherapy

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus
Clinical trial NCT01335464 (phase 3, status: completed)
Conditions: pulmonary fibrosis
ICD codes: J84.10, J84.112, E84.0, J84.178
Drugs: placebo, bibf 1120
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1
Eligibility criteria:

        Inclusion criteria:

          1. Age >= 40 years;

          2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European
             Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic
             Association (ALAT) IPF guideline for diagnosis and management, within 5 years;

          3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if
             available surgical lung biopsy pattern, as assessed by central reviewers, are
             consistent with diagnosis of IPF

          4. Dlco (corrected for Hb): 30%-79% predicted of normal;

          5. FVC>= 50% predicted of normal

        Exclusion criteria:

          1. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 1.5 x Upper Limit
             of Normal (ULN)

          2. Bilirubin > 1.5 x ULN;

          3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC < 0.7);

          4. Patient likely to have lung transplantation during study (being on transplantation
             list is acceptable for participation);

          5. Myocardial infarction within 6 months;

          6. Unstable angina within 1 month;

          7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic
             anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event
             within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or
             ulcers or major injury or surgery within 3 months);

          8. Thrombotic risk (inherited predisposition; history of thrombotic event (including
             stroke and transient ischemic attacks) within 12 months;

          9. International normalised ratio (INR) > 2, prolongation of prothrombin time (PT) and
             partial thromboplastin time (PTT) by > 50% of institutional ULN);

         10. N-ACetyl Cystein, prednisone > 15mg/day or equivalent received within 2 weeks of visit
             1;

         11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of
             visit 1;
Clinical trial NCT00391209 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: simplified diabetes regimen starting with a fixed dose of human insulin inhalation powder, intensive diabetes management starting with an adjusted dose of human insulin inhalation powder
SMILES: CCO, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus for at least 6 months

          -  Have a HbA1c greater than 7.0% and less than or equal to 10.5% at screening.

          -  Patients who have been treated with the following regimen:

        One or more oral antihyperglycemic medications on a stable dose for at least 6 weeks (12
        weeks for thiazolidinediones [TZDs]),

        AND

        have been on insulin for 14 days or less throughout life and have not taken insulin within
        6 months,

        AND

        are candidates for insulin therapy, in the opinion of the investigator.

        Exclusion Criteria:

          -  Pregnancy

          -  Smoker

          -  History of more than two episodes of severe hypoglycemia during the 6 months prior to
             study entry

          -  Diagnosed with pneumonia in the 3 months prior to screening

          -  Patients who have received systemic glucocorticoid therapy within 3 months prior to
             study entry

          -  History of renal transplantation

          -  History of lung transplantation

          -  Active or untreated malignancy

          -  Treated with Incretin mimetics
Clinical trial NCT01577082 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: chf1535 200/6 µg, bdp 100 µg
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Main Inclusion Criteria:

          -  Male or female patients aged > 18 years.

          -  Patients with persistent asthma not optimally controlled (GINA 2010) on high doses of
             ICS or medium dose of ICS+LABA at a stable dose for at least 4 weeks prior to
             screening.

          -  Patients with FEV1 >= 40% and < 80% of predicted for the patient normal value and at
             least 0.9 L.

          -  Patients with a documented positive response to the reversibility test, defined as
             ΔFEV1 >= 12% and >= 200 mL over baseline, within 30 minutes after administration of
             400 μg of salbutamol pMDI.

          -  At screening and at the end of the run-in period, patients with not adequately
             controlled asthma according to GINA 2010 and with score at the Asthma Control
             Questionnaire (ACQ)> 0.75

        Main Exclusion Criteria:

          -  History of near fatal asthma or of a past hospitalisation for asthma in Intensive Care
             Unit or of frequent exacerbations (3 or more asthma exacerbations/ year).

          -  Hospitalisation, Emergency Room admission or use of systemic steroids (more than 3
             days) for asthma exacerbation in the 4 weeks prior to screening visit and during the
             run-in period.

          -  Symptomatic infection of the lower airways in the 4 weeks before the screening visit.

          -  Current or ex-smokers with total cumulative exposure equal or more than 5 pack-years
             and /or having stopped smoking one year or less prior to screening visit.

          -  Patients with a clinically significant abnormality at 12-lead ECG or presenting a QTcB
             interval value in ECG > 450 msec in males or > 470 msec in females).
Clinical trial NCT01301963 (phase 3, status: terminated)
Conditions: refractory multiple myeloma
ICD codes: D46.4, D46.1, D46.A, D46.0, D46.20, D46.21, D46.22
Drugs: plerixafor
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of MM by International Myeloma Working Group Criteria

          -  In first or second complete or partial remission or stable refractory but not actively
             progressing myeloma according to the classifications provided by The Center for
             International Blood & Marrow Transplant Research

          -  Received at least 2 cycles of lenalidomide therapy

          -  Patients with MM scheduled to undergo stem cell harvest for possible allogeneic stem
             cell transplant (ASCT)

          -  At least 2 weeks since last exposure to lenalidomide

          -  Eastern Cooperative Oncology Group performance status of 0 or 1

          -  Prior to the start of mobilization:

               -  white blood cell count >/= 2.5 x 10^9/L

               -  absolute neutrophil count >/= 1.2 x 10^9/L

               -  platelet count >/=100 x 10^9/L

               -  creatinine clearance >/= 30mL/minute

          -  If childbearing potential, must either agree to complete abstinence from heterosexual
             intercourse or effective means of contraception during stem cell mobilization; female
             patients will undergo pregnancy test prior to stem cell mobilization therapy

        Exclusion Criteria:

          -  Had prior autologous or allogeneic transplantation

          -  Received pegfilgrastim within 3 weeks or G-CSF within 14 days of first dose of G-CSF
             for mobilization

          -  Failed previous hematopoietic stem cell collections or collection attempts

          -  Received radiation therapy to the pelvic area

          -  Received lenalidomide within 2 weeks of first dose of G-CSF for mobilization

          -  Had received experimental therapy within 4 weeks of enrolling in study

          -  Current or prior history of other malignancies, excluding basal cell carcinoma of the
             skin
Clinical trial NCT00711529 (phase 3, status: completed)
Conditions: breast cancer, hot flashes
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gabapentin
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion criteria:

          -  Women with histologic confirmation of a diagnosis of infiltrating carcinoma of the
             breast are eligible for participation.

          -  Women with non-invasive or pre-invasive lesions of the breast, including but not
             limited to ductal carcinoma in situ (DCIS), atypical ductal hyperplasia (ADH) or
             lobular carcinoma in situ (LCIS) are eligible for participation.

          -  Women with a known breast cancer susceptibility gene (eg, BRCA) mutation or strong
             family history of breast cancer are eligible.

          -  Any woman age 60 years or more who cannot take estrogen therapy because of a real or
             perceived risk of developing breast cancer are eligible.

          -  Women under the age of 60 with a Gail model score of 1.6% or more are eligible.

          -  Subjective report of at least one daily hot flash.

          -  Able to provide voluntary informed consent.

          -  ≥ 18 years-old. There will be no upper limit for age inclusion.

          -  Karnofsky performance status > 70%.

          -  Women with a history of breast cancer must have undergone treatment with curative
             intent.

          -  ≥ 4 weeks from completion of chemotherapy or radiation therapy, where appropriate.

          -  adequate hematopoietic function (ANC ≥ 1500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin ≥
             8 g/dL)

          -  adequate renal and hepatic function [Bilirubin ≤ 1.5 times upper limit of normal
             (ULN), serum glutamic-oxaloacetic transaminase (SGOT) ≤ 2.5x ULN, Alkaline phosphatase
             ≤ 2.5x ULN, and Creatinine ≤ 2x ULN].

          -  No clinical evidence of disease (complete remission).

          -  Patients receiving neoadjuvant therapy will be eligible following completion of all
             adjuvant chemotherapy if indicated.

          -  Patients receiving hormonal therapy in lieu of or following chemotherapy will be
             eligible to participate.

          -  Patients must have access to a compact disk player.

        Exclusion criteria:

          -  History or active secondary cancer within the last 5 years (except for superficial
             basal cell skin cancers).

          -  Any residual chemotherapy-induced CTCv3.0 Grade 2 or greater non-hematological
             toxicity.

          -  Unable to give informed consent or unable to adhere to protocol.

          -  Any serious medical or psychiatric illness likely to interfere with participation in
             this clinical study, concurrent uncontrolled illness, or ongoing or active infection
             will be excluded.

          -  Any history of alcohol or drug abuse.

          -  Allergy to gabapentin.

          -  History of seizure disorder.
Clinical trial NCT00396565 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: er oros paliperidone, placebo, olanzapine
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have given their own consent in writing to participate in the study

          -  Patients diagnosed with schizophrenia according to the diagnostic criteria of DSM-IV
             (Diagnostic and Statistical Manual of Mental Disorders, 295.30, 295.10, 295.20,
             295.90, 295.60)

          -  Patients who have acute symptoms of schizophrenia

          -  Both inpatients and outpatients are acceptable

        Exclusion Criteria:

          -  A DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) of a mental disease
             diagnosis other than schizophrenia

          -  A DSM-IV diagnosis of substance-related disorder (except nicotine dependence and
             caffeine dependence) within 180 days before the screening test

          -  Total PANSS (Positive and Negative Syndrome System) score at the screening test <70 or
             >120

          -  Patients treated with three or more types of antipsychotic within 28 days before the
             screening test

          -  Parkinson's disease (except for those with drug-induced extra pyramidal symptoms)

          -  Patients with a complication of or a past history of cerebrovascular accident

          -  Patients with a complication of or a past history of diabetes mellitus
Clinical trial NCT01370005 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2, hypertension
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: placebo, bi 10773, placebo, bi 10773, placebo, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Patients >=18 years with type 2 diabetes

          2. HbA1c of >= 7.0% (53 mmol/mol) and =< 10% (86 mmol/mol)

          3. Mean seated systolic blood pressure 130-159 mmHg and diastolic blood pressure 80-99
             mmHg

        Exclusion criteria:

          1. Uncontrolled hyperglycaemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an
             overnight fast before randomization

          2. Known or suspected secondary hypertension

          3. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or
             transient ischemic attack within 3 months prior to informed consent
Clinical trial NCT00148798 (phase 3, status: completed)
Conditions: non small cell lung cancer (nsclc)
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cetuximab + cisplatin + vinorelbine, cisplatin + vinorelbine
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of histologically or cytologically confirmed NSCLC, stage IIIb with
             documented malignant pleural effusion or stage IV

          -  Immunohistochemical evidence of EGFR expression on tumor tissue

          -  Presence of at least 1 bi-dimensionally measurable index lesion, whereby index lesions
             must not lie in an irradiated area

        Exclusion Criteria:

          -  Previous exposure to monoclonal antibodies, signal transduction inhibitors or
             EGFR-targeting therapy

          -  Previous chemotherapy for NSCLC

          -  Documented or symptomatic brain metastasis

          -  Superior vena cava syndrome contra-indicating hydration

          -  Previous malignancy in the last 5 years except basal cell carcinoma of the skin or
             pre-invasive carcinoma of the cervix